Hi,
Anyone attended the AGM concluded on September 30?
Please do share any notes on the same.
Thanks
Posts tagged Value Pickr
Alembic & Alembic Pharma (02-10-2015)
Hi Ankit,
Yes, thanks for the awesome compilation. Its the most comprehensive work I have come across. I saw the file only few days back. To me Alembic pipeline looks to be the strongest among companies of this size, maybe better than many bigger companies too. I have made a mind map of Alembic pharma. Will upload it once I am done.
The valuations on trailing basis (46x) appear high compared to the fair PE band of 25-30 assigned to Alembic in the VP public PF thread earlier. Assuming a 30% growth for 1 yr, it comes to 35 times 1 year forward PE. This is definitely pricey but there is a good visibility for next 3 years.
Does anyone have an idea about the bioequivalence activities of Alembic? As per my understanding, one success here can be a blockbuster.
MPS Ltd (02-10-2015)
From current rate I see limited downsides for MPS so opportunity cost purely depends on what other opportunities you have at this point of time because I see scope for good appreciation even from here on for MPS because there seem to be many ammunitions still left in company's arsenal.....key monitorable is how well company uses the cash it has whenever it does......even if management can generate less than half the returns from acquired company than it generated in case of Macmillan then wealth creation for investors could be significant which even at current corrected rates many high quality management mid & small caps might not be capable of delivering.......company should not burn cash in any way by making high loss making acquisitions or by buying hgh debt......if at FY18 dreamed scale of management, a 25 % + EBITDA margin is maintained consistently with healthy balance sheet then current valuations will look extremely appealing for not only long but medium term investors too.
Rgds.
Discl - Invested in MPS
Note - This is not a buy/sell/hold recommendation and is only part of general discussion.
US based NRI’s – How do you guys invest in equity now? (02-10-2015)
FATCA issues can be avoided by maintaining proper foreign allocation. Tax questions in india were based on the source of income for my parents..
I am more looking to get info on how to open a demat account with NRO linked account in india so that i can have shares on my name for long term and is repatriable later. Apparently, most of the brocker firms not entertaining US/canada based NRI's. US based NRI's please help me with your comments.
Please msg me privately or @ bijoy.finance@gmail.com if you want things to keep personal. thanks.
NCL Industries – Resumption of growth? (02-10-2015)
I haven't looked into the businesses you have mentioned. Thus I cannot comment on them.
One positive that I liked about NCL though was, increase in promoter holding at current levels. If promoters show confidence about the business and things look set for near future, it's good enough for me to take a position.
US based NRI’s – How do you guys invest in equity now? (01-10-2015)
Hi All,
I am facing the same issue as Bijoy and would like to get some answers too.
I used to Invest in India before coming to the US, but since FATCA, all the red tape paperwork has all become a big headache.
Best Regards
NCL Industries – Resumption of growth? (01-10-2015)
Why shouldn't we buy other cement companies like Sagar or Mangalam Cement as they look to be cheaper than NCl with more capacities and higher realizations ?
Hitesh portfolio (01-10-2015)
Hitesh what do you think can be the target for Pi vs Gruh in the next few months ..will pi not outpace gruh do you think
Varun 2020 portfolio – 2 strategies (01-10-2015)
Portfolio Update - Period of inactivity in this week except nibbling at Edelweiss and marginal increase of stake in Axis. Portfolio performed slightly better than Nifty benchmark.
Some positive news on Biocon - lets see how this pans out next few weeks. The consolidation with a slight upward bias in L&T finance and DHFL is inspiring confidence. Lupin now seems to head to 2400 before another consolidation happens.
Varun 2020 portfolio – 2 strategies (01-10-2015)
Portfolio Update - Period of inactivity in this week except nibbling at Edelweiss and marginal increase of stake in Axis. Portfolio performed slightly better than Nifty benchmark.
Some positive news on Biocon - lets see how this pans out next few weeks. The consolidation with a slight upward bias in L&T finance and DHFL is inspiring confidence. Lupin now seems to head to 2400 before another consolidation happens.